Roy Pettipher
Oprichter bij Orca Pharmaceuticals Ltd.
Profiel
Roy Pettipher is the founder of Orca Pharmaceuticals Ltd.
which was founded in 2012, where he holds the title of Chief Scientific Officer.
He is currently working as a Research Director at Atopix Therapeutics Ltd.
Dr. Pettipher's former positions include Pharmacology Director at Oxagen Ltd., Principal at Pfizer Inc., and Principal at Wellcome Plc.
Actieve functies van Roy Pettipher
Bedrijven | Functie | Begin |
---|---|---|
Orca Pharmaceuticals Ltd.
Orca Pharmaceuticals Ltd. BiotechnologyHealth Technology Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom. | Oprichter | 01-01-2012 |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | - |
Eerdere bekende functies van Roy Pettipher
Bedrijven | Functie | Einde |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
Wellcome Plc
Wellcome Plc Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK. | Corporate Officer/Principal | - |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PFIZER, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Wellcome Plc
Wellcome Plc Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK. | Commercial Services |
Orca Pharmaceuticals Ltd.
Orca Pharmaceuticals Ltd. BiotechnologyHealth Technology Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Health Technology |